Severe cutaneous adverse reactions (SCARs) mediated by cytotoxic T lymphocytes, including SJS and TEN, have been shown to be effectively treated with anti-TNF-α biologic agents, and Etanercept is one of anti-TNF-α biologic agents (19). Here, TNF is linked to Schwartz-Jampel syndrome.